Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Roku

Block

Teladoc

Tesla

Yields are on the rise and valuation-propelled tech is getting deflated.

Bulls & Bears Battle It Out In Big Tech

One analyst thinks the company's foundational gene-editing tools have far more potential than many realize.

Is CRISPR Stock Heading to $160 in 2021?

BioMarin Pharmaceutical

General Electric

Anthem

American Outdoor Brands

American Water Works

Charles Schwab

Wheaton Precious Metals

Yext

With the trading day about halfway over, the broad markets had managed to push higher on the day, despite dipping into the red earlier.

Anthem, BioMarin, CRISPR, GE and More Thursday Afternoon Analyst Calls

Churchill Capital Corp IV

Virgin Galactic

The companies with game-changing technology are often the best growth picks.

Why It's Time to Go All-In on These 3 Revolutionary Stocks

Fulgent Genetics

These stocks made investors a lot of money in 2020. Which one will be the better choice this year?

Better Buy: CRISPR vs. Fulgent Genetics

The Buzzing Gene-Editing Market Of Crispr Therapeutics

The gene editing sector remains red-hot as the promise to transform the way disease is treated. CRISPR Therapeutics seems primed to exploit the technology for outsized share gains.

CRISPR Therapeutics: Roadblock Ahead

Apple

DocuSign

Plug Power

Veeva Systems

Zoom Video

Overvalued stocks are easy to find using metrics which indicate a stock should trade for less. But these ones keep bucking their critics.

7 Overvalued Stocks Investors Just Don't Get Tired Of

A few months back we talked about why the rally in CRSP stock may continue given the positive developments around CTX001, an experimental gene therapy for people with sickle cell disease and transfusion-dependent beta thalassemia. CRSP stock extended its rally from levels of around $107.

Time To Book Profits In CRISPR Stock After A 5x Rally?

Pure Storage

Spotify

Investors have done great in ARKK, but buying these three ARK Innovation stocks with hedged strategies is today's smart money trade. The post 3 ARK Innovation Stocks to Buy Right Now appeared first on InvestorPlace.

3 ARK Innovation Stocks to Buy Right Now

We are glad to announce that we have added Catherine Wood (Trades, Portfolio)'s ARK Investment Management as one of our Premium Gurus.

Top 5 Holdings of Catherine Wood's ARK Investment

CRISPR Therapeutics (CRSP) misses estimates for both earnings and revenues in the fourth quarter of 2020. Focus on pipeline development.

CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Fall Y/Y

- More than 20 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021 -

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Abbott Labs

Want to play it safe in a volatile market? Go for these three top-notch healthcare picks.

3 Top Healthcare Stocks to Buy in February

Bear of the Day: CRISPR Therapeutics (CRSP)

Clough Global Opportunities Fund

Clough Global Equity Fund

Clough Global Dividend and Income Fund

PennyMac Financial Services

The Clough funds all have impressive records. GLV previously paid a higher distribution yield even though it didn't earn as much as its two siblings, GLO and GLQ. That's been rectified with the big dividend increases (21%) for GLO and GLQ and the slight (4%) cut to GLV's payout.

The Clough Closed-End Funds Continue To Perform

On CRISPR Therapeutics' (CRSP) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its lead gene-editing candidate, CTX001.

CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021, at 3:30 p.m. ET.

CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day

Editas Medicine

Which of these two hot gene therapy stocks is the better buy?

Better Buy: CRISPR Therapeutics vs. Editas Medicine

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Philippe Drouet as Chief Commercial Officer. Mr. Drouet brings more than 20 years of leadership experience in global pharmaceutical marketing and joins CRISPR Therapeutics to develop and oversee the Company's global commercialization efforts.

CRISPR Therapeutics Announces the Appointment of Philippe Drouet as Chief Commercial Officer

CRISPR Therapeutics stock, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, has plunged by 14% over the last 10 trading days, and it is down 10% over the last 5 trading days. Earlier this month, CRSP stock made its lifetime high of $210, and it.

What's Next For CRISPR Stock After A 14% Fall?

Corcept Therapeutics

Fate Therapeutics

Jounce Therapeutics

Lexicon Pharmaceuticals

Time will always be on the investor's side.

Got $5,000 and 5 Years to Wait? Buy These 5 Hot Biotech Stocks Now

Invitae

Genetic testing companies have to appeal to several stakeholders in the healthcare system in order to make it to the next level.

Here's How the Genetic Testing Industry Can Get Even Bigger

Johnson & Johnson

SPDR S&P 500 ETF Trust

Vertex Pharmaceuticals

Vanguard Total Stock Market ETF

With a nest egg this sizable, you'll need to find more than one place to put your money so it keeps growing.

Where to Invest $1 Million Right Now

Beam Therapeutics

Intellia Therapeutics

SpringWorks Therapeutics Inc

Among the public companies that made the BioSpace list of the top up and coming life sciences firms in 2019 and 2020, the majority have seen gains in their share prices. Given this metric, investors might want to track the progress of those still-private firms in the event they take the initial public offering route down the line.

Beam, SpringWorks Biggest Gainers on BioSpace List

News for CRISPR Therapeutics Stock (CRSP)